Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.31 |
| ▸ | PLCG1 | P19174 | 1/20 | 0.30 |
| ▸ | P2RY1 | P47900 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18467354 | 0.85 | TLR8 (0.32) | TDP1LMNAHTTNPSR1KDM4E | |
| SCHEMBL231343 | 0.81 | CA2 (0.41) | TDP1LMNAHTTNPSR1KDM4E | |
| SCHEMBL21150744 | 0.80 | TDP1 (0.35) | TDP1LMNAHTTNPSR1KDM4E | |
| Ammonia Solution, Strong SCHEMBL28823003 | 0.79 | CA2 (0.39) | TDP1LMNAHTTNPSR1KDM4E | |
| SCHEMBL19040928 | 0.78 | P2RX7 (0.37) | TDP1HTTNPSR1KDM4EKMT2A | |
| SCHEMBL20031355 | 0.78 | SSTR4 (0.42) | ALDH1A1SSTR4 | |
| SCHEMBL20686388 | 0.77 | NOS2 (0.45) | TDP1HTTKDM4EALDH1A1KMT2A | |
| SCHEMBL1132774 | 0.77 | TDP1 (0.35) | TDP1HTTNPSR1ALDH1A1KMT2A | |
| SCHEMBL22023658 | 0.77 | NAPRT (0.36) | TDP1NPSR1ALDH1A1KMT2AHRH3 | |
| SCHEMBL18745368 | 0.77 | TDP1 (0.38) | TDP1HTTNPSR1KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200140438-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | DOMAIN THERAPEUTICS (FR) | 2020-05-07 | — | — | US | disclosed |
| US-10266496-B2 | Carboxy substituted (hetero) aromatic ring derivatives and preparation method and uses thereof | SUNSHINE LAKE PHARMA CO., LTD. (CN) | 2019-04-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200140438-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS AS ALLOSTERIC MODULATORS OF GROUP II METABOTROPIC GLUTAMATE RECEPTORS | GRM3, GRM1, GRM2 | TDP1 4042/4885LMNA 4813/4885HTT 810/4885 |
| US-10266496-B2 | Carboxy substituted (hetero) aromatic ring derivatives and preparation method and uses thereof | XDH, ABCG2, SLC7A1 | TDP1 931/4885LMNA 2343/4885HTT 1666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.